Recent Updates
Recently added Catalysts

Alzheimer's Disease: 5 biotech companies with clinical-stage programmes

Neurology & PsychiatryOrphan cornerData as of 2026-09-04

Competitors5in the clinic
Median market cap$397Muniverse median $1.20B
Allocated capital$2.9B$16.6B competing
Phase 3 or filed01 mid, 4 early
Pure plays2this indication only
Capital rank68/299crowding rank 36

Alzheimer's Disease sits in the orphan corner of the map: 5 developers, none of them large, with a median market cap of $397M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

ARWR carries 74% of the $16.6B competing here, more than the other 4 companies combined.

$2.9B of allocated capital sits in Alzheimer's Disease, 68th of 299 indications, and 2 of the 5 companies are pure plays that trade on this indication alone.

Companies developing drugs for Alzheimer's Disease 5

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ABOSAcumen PharmaceuticalssabirnetugPhase 21$223MYes1 31 Dec 2026
ARWRArrowhead PharmaceuticalsARO-MAPTPhase 11$12.2BNo7 31 Dec 2026
DNLIDenali TherapeuticsDNL628Phase 12$3.6BNo5 31 Dec 2026
LXEOLexeo TherapeuticsLX1001Phase 11$397MNo3 31 Dec 2026
PMNProMIS NeurosciencesPMN310Phase 11$116MYes1 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ARWR holds 74% of the $16.6B competing in this indication.

Why Alzheimer's Disease is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Alzheimer's Disease has 5 competitors and a median of $397M.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Excessive Daytime Somnolence1 company · $2.7B · median $10.9BUncontestedSmoking Cessation1 company · $2.7B · median $10.9BUncontestedChorea1 company · $2.7B · median $16.1BUncontestedObsessive Compulsive Disorder1 company · $2.7B · median $16.1BUncontestedFriedreich Ataxia5 companies · $3.2B · median $941MOrphan cornerNarcolepsy Type 11 company · $2.6B · median $7.9BUncontestedSCN2A Encephalopathy1 company · $3.3B · median $9.9BUncontestedTonic-Clonic Epilepsy1 company · $3.3B · median $9.9BUncontested

Alzheimer's Disease pipeline questions

Which biotech companies are developing drugs for Alzheimer's Disease?

Acumen Pharmaceuticals (ABOS, sabirnetug, Phase 2); Arrowhead Pharmaceuticals (ARWR, ARO-MAPT, Phase 1); Denali Therapeutics (DNLI, DNL628, Phase 1); Lexeo Therapeutics (LXEO, LX1001, Phase 1); ProMIS Neurosciences (PMN, PMN310, Phase 1). Those are the 5 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Alzheimer's Disease.

How advanced is the Alzheimer's Disease pipeline?

Of the 5 clinical-stage programmes in Alzheimer's Disease, 0 are in Phase 3 or filed, 1 is in mid-stage development and 4 are in early-stage development.

Which company leads the Alzheimer's Disease field?

ARWR is the largest developer in Alzheimer's Disease, holding 74% of the $16.6B of market capitalisation competing in the indication. The median competitor is worth $397M.

When is the next Alzheimer's Disease catalyst?

The next dated catalyst in Alzheimer's Disease is PMN on 30 Sep 2026. 5 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map